Nasdaq GlobeNewswire

Albireo to Present A4250 Clinical Data at the 2015 AASLD Annual Meeting

Del

GOTHENBURG, Sweden and London, 2015-11-12 13:00 CET (GLOBE NEWSWIRE) -- Albireo Limited, a clinical-stage biopharmaceutical company developing through its operating subsidiary novel bile acid modulators to treat rare pediatric liver diseases, NASH, and gastrointestinal disorders, announced today that Albireo scientists will present a poster of clinical data for A4250 at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting being held from November 13 through November 17 in San Francisco, California. A4250, Albireo's lead product candidate, is being developed as a treatment for rare pediatric liver diseases and nonalcoholic steatohepatitis (NASH).

Albireo's poster, titled "The Ileal Bile Acid Transporter Inhibitor A4250 Modulates Bile Acid Synthesis and Decreases Serum Bile Acids," is scheduled to be presented on Sunday, November 15, 2015. The poster includes data from a double-blind Phase 1 single and multiple ascending dose clinical trial designed to assess the safety, pharmacokinetics and pharmacodynamics of A4250 in healthy volunteers.

"Our data to be presented at the AASLD meeting highlight the promise of A4250 in reducing serum bile acids, which are typically elevated in cholestatic liver disease and often associated with severe liver damage, as well as the compound's minimal systemic exposure at therapeutically relevant doses and favorable safety and tolerability profile," said Ron Cooper, Albireo's President and Chief Executive Officer. "Enrollment continues in two ongoing Phase 2 clinical trials of A4250, one in pediatric cholestatic pruritus and one in primary biliary cirrhosis."

About A4250

A4250 is a first-in-class product candidate in development for rare pediatric cholestatic liver diseases, including progressive familial intrahepatic cholestasis (PFIC), and nonalcoholic steatohepatitis (NASH). A4250 is a highly potent and selective inhibitor of the ileal bile acid transporter that acts locally in the gut, has minimal systemic exposure and is excreted substantially intact, resulting in a reduced risk of systemic side effects and undesirable drug-drug interactions. A4250, which is currently being evaluated in Phase 2 clinical trials in pediatric cholestatic pruritus and primary biliary cirrhosis, has been granted orphan drug designation in the United States and the European Union for PFIC, as well as certain other cholestatic liver diseases.

About Albireo

Albireo Limited is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel locally acting bile acid modulators to treat diseases in which there is high unmet medical need, including rare pediatric liver diseases, nonalcoholic steatohepatitis (NASH), and debilitating gastrointestinal disorders. Albireo's clinical pipeline includes two Phase 2 product candidates and one Phase 3 product candidate. Albireo was spun out from AstraZeneca in 2008 and is backed by top-tier life science investors such as Phase IV Ventures, TPG Biotech, TVM Capital Life Science and Aberdeen Asset Management, as well as AstraZeneca.

Albireo Limited is incorporated and registered in England and Wales, and its wholly owned subsidiaries are located in Gothenburg, Sweden (including its operating subsidiary Albireo AB) and Boston, Massachusetts. For more information on Albireo, please visit www.albireopharma.com.

Albireo is a registered trademark of Albireo AB in key pharmaceutical markets in Europe.

         CONTACT:
         Albireo Contact:
         Jan Mattsson
         Chief Operating Officer
         Tel: +46 31 741 14 80
         info@albireopharma.com

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Olympus Labs Partners with Leading Korean Fintech Company Metaps Plus19.1.2018 00:03Pressemelding

Gibraltar, Jan. 18, 2018 (GLOBE NEWSWIRE) -- Olympus Labs is quickly becoming an emerging global leader in the cryptocurrency-based financial product space, and on the heels of a successful token sale, Olympus is partnering with Seoul-based corporation Metaps Plus, a leading Korean fintech company and mobile marketing platform developer. This news comes shortly after the company announced OKEx, as its official exchange for the company's token MOT. "This is an amazing partnership for us, as it will allow us to hit the Korean market in a big way. We will be able to tap directly into the tens of millions of users on the Metaps Plus platform, allowing users to access financial products created by Olympus," said Kai Chen, CEO of Olympus Labs. "This is a key milestone as it demonstrates that Olympus products can be integrated in third party platforms such as mobile apps, wallets, exchanges, and even physical atms and pos systems, allowing users throughout the world access to Olympus products

Forward Industries Acquires Intelligent Product Solutions18.1.2018 23:54Pressemelding

WEST PALM BEACH, Fla. and HAUPPAUGE, N.Y., Jan. 18, 2018 (GLOBE NEWSWIRE) -- Forward Industries (NASDAQ:FORD) today announced the acquisition of Intelligent Product Solutions (IPS), an industry leading product design and development company based in Long Island, New York for a material consideration comprising of cash, equity, and contingent earn outs. IPS clients include leading brands in consumer electronics, medical devices, enterprise and security solution providers and Internet of Things connected solutions, including Google, Physio Control, PepsiCo, Motorola, ABInBev, Zebra and Charity Water. Commenting on the transaction, Terry Wise, CEO of Forward Industries remarked, "I am delighted and excited with the acquisition of IPS. The company is an excellent strategic fit for Forward Industries. Its expertise and strong track record in designing connected/IOT products and developing products such as the AdhereTech 'smart' pill bottle will significantly strengthen and contribute to For

VITEC to Highlight EZ TV IPTV and Digital Signage Platform in First ISE Appearance18.1.2018 21:06Pressemelding

PARIS, Jan. 18, 2018 (GLOBE NEWSWIRE) -- In its first-ever attendance at Integrated Systems Europe (ISE), VITEC, a worldwide leader in advanced video encoding and streaming solutions, will showcase EZ TV - a market-leading, broadcast-grade IPTV and digital signage platform with key installations in Europe and the U.S. Targeted to enterprises, sports stadiums and arenas, and government agencies, EZ TV combines low-latency, broadcast-quality IPTV distribution with powerful digital signage capabilities to give audiences a more engaging and interactive experience. "As Europe's largest show for AV systems integrators, ISE is the perfect forum for us to present our EZ TV IPTV platform," said Bruno Teissier, sales and marketing director, VITEC. "We're looking forward to showing ISE attendees how they can help their customers distribute broadcast-quality IPTV content and access powerful digital signage capabilities in an all-in-one, integrated solution." Designed to integrate seamlessly with a

Brookfield Asset Management Notice of 2017 Year End Results Conference Call and Webcast18.1.2018 16:12Pressemelding

Date: Thursday, February 15, 2018 Time: 11:00 a.m. (Eastern Time) BROOKFIELD, News, Jan. 18, 2018 (GLOBE NEWSWIRE) -- You are invited to participate in Brookfield Asset Management's 2017 Year End Results Conference Call & Webcast on Thursday, February 15, 2018 at 11:00 a.m. (Eastern Time) to discuss with members of senior management our results and current business initiatives. These results will be released on February 15th before 7:00 a.m. (Eastern Time) and will be available following the release on our website at www.brookfield.com "News - Press Releases." The Conference Call will also be Webcast live on our website, where it will be archived for future reference. To participate in the Conference Call, please dial 1-866-521-4909 toll free in North America, or for overseas calls please dial 1-647-427-2311 at approximately 10:50 a.m. The Conference Call will also be Webcast live at https://event.on24.com/wcc/r/1585364/9F53C4FB4A83FF2D32296C84535D6A34. For those unable to participate

LifeSci Advisors Continues Expansion of U.S. Investor Relations Team with Appointment of Industry Veteran Monique Kosse18.1.2018 14:30Pressemelding

NEW YORK, Jan. 18, 2018 (GLOBE NEWSWIRE) -- LifeSci Advisors, LLC (the "Company" or "LifeSci"), the leading international investor relations and corporate communications firm dedicated to the life sciences sector, today announced the appointment of Monique Kosse as Managing Director. Ms. Kosse will contribute to managing new and existing client relationships in the pharmaceutical, biotech, and medtech industries. Monique brings to LifeSci nearly 20 years of Wall Street experience. Her expertise includes roles as both a senior institutional investment analyst and as a trusted investor relations advisor. Before joining LifeSci, Monique was a founding partner at Access Capital Advisors, where she partnered with senior management teams to develop tailored IR strategies designed to best convey each client's value proposition to Wall Street. She and her partner thoughtfully crafted messaging, developed positioning, and targeted key investors. Prior to her career in investor relations, Moniqu

FutureWAN'18 Brings Industry Leaders Together for Global SD-WAN Summit18.1.2018 14:00Pressemelding

Amazon Web Services, IDC, Cisco and ServiceNow Among Featured Presenters SAN JOSE, Calif., Jan. 18, 2018 (GLOBE NEWSWIRE) -- The FutureWAN'18 Summit today announced keynote presenters and the full agenda for its four day virtual summit. The global SD-WAN summit will feature analysts, technology providers, enterprise IT users and service providers. FutureWAN'18 will share experiences and deliver comprehensive education on the major aspects of enterprise WAN problems. Running Jan. 23 through Jan 26, the virtual event will feature multiple tracks, including Cloud, Security, Enterprise SD-WAN (Operations) and Managed Services. SD-WAN's growth has created new and exciting growth opportunities for service providers and cloud players. The FutureWAN'18 summit will feature presentations by key players, including Verizon, BT, Orange Business Services and Amazon Web Services, among others, that are taking advantage of this new frontier. In addition, the summit will feature analyst presentations b

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom